Literature DB >> 12857964

Regulation, counter-regulation, and immunotherapy of autoimmune responses to immunologically privileged retinal antigens.

Rachel R Caspi1.   

Abstract

Our interests revolve around the study of biological mechanisms regulating self-tolerance to immunologically privileged retinal proteins that serve as targets in sight-threatening autoimmune uveitic disease. These studies are aimed at understanding how selftolerance to these antigens develops during ontogeny and is maintained during adulthood, the processes involved in its pathological breakdown, the regulatory mechanisms that bring about remission and recovery, and, finally, how we can utilize knowledge of these processes for therapeutic restoration of tolerance. To answer these questions, we use the experimental autoimmune uveitis (EAU) model in rats and mice. Because of the commonality of underlying immunological mechanisms, lessons and concepts learned in experimental ocular models are applicable to other disease entities, and, conversely, data gleaned from other autoimmune diseases are applicable to the study of uveitis.

Entities:  

Mesh:

Year:  2003        PMID: 12857964     DOI: 10.1385/IR:27:2-3:149

Source DB:  PubMed          Journal:  Immunol Res        ISSN: 0257-277X            Impact factor:   2.829


  37 in total

Review 1.  Immunopathogenic mechanisms in intraocular inflammation.

Authors:  J V Forrester; P G McMenamin
Journal:  Chem Immunol       Date:  1999

2.  Oral tolerance in a murine model of relapsing experimental autoimmune uveoretinitis (EAU): induction of protective tolerance in primed animals.

Authors:  S R Thurau; C C Chan; R B Nussenblatt; R R Caspi
Journal:  Clin Exp Immunol       Date:  1997-08       Impact factor: 4.330

3.  Recruitment of antigen-nonspecific cells plays a pivotal role in the pathogenesis of a T cell-mediated organ-specific autoimmune disease, experimental autoimmune uveoretinitis.

Authors:  R R Caspi; C C Chan; Y Fujino; F Najafian; S Grover; C T Hansen; R L Wilder
Journal:  J Neuroimmunol       Date:  1993-09       Impact factor: 3.478

4.  Genetic control of susceptibility to experimental autoimmune uveoretinitis in the mouse model. Concomitant regulation by MHC and non-MHC genes.

Authors:  R R Caspi; B G Grubbs; C C Chan; G J Chader; B Wiggert
Journal:  J Immunol       Date:  1992-04-15       Impact factor: 5.422

5.  Transgenic expression of an immunologically privileged retinal antigen extraocularly enhances self tolerance and abrogates susceptibility to autoimmune uveitis.

Authors:  H Xu; E F Wawrousek; T M Redmond; J M Nickerson; B Wiggert; C C Chan; R R Caspi
Journal:  Eur J Immunol       Date:  2000-01       Impact factor: 5.532

6.  Early onset photoreceptor abnormalities induced by targeted disruption of the interphotoreceptor retinoid-binding protein gene.

Authors:  G I Liou; Y Fei; N S Peachey; S Matragoon; S Wei; W S Blaner; Y Wang; C Liu; M E Gottesman; H Ripps
Journal:  J Neurosci       Date:  1998-06-15       Impact factor: 6.167

7.  Endogenous systemic IFN-gamma has a protective role against ocular autoimmunity in mice.

Authors:  R R Caspi; C C Chan; B G Grubbs; P B Silver; B Wiggert; C F Parsa; S Bahmanyar; A Billiau; H Heremans
Journal:  J Immunol       Date:  1994-01-15       Impact factor: 5.422

8.  Regulation of experimental autoimmune uveitis in rats--separation of MHC and non-MHC gene effects.

Authors:  S Hirose; K Ogasawara; T Natori; Y Sasamoto; S Ohno; H Matsuda; K Onoé
Journal:  Clin Exp Immunol       Date:  1991-12       Impact factor: 4.330

9.  Failure to suppress the expansion of the activated CD4 T cell population in interferon gamma-deficient mice leads to exacerbation of experimental autoimmune encephalomyelitis.

Authors:  C Q Chu; S Wittmer; D K Dalton
Journal:  J Exp Med       Date:  2000-07-03       Impact factor: 14.307

10.  Myelin basic protein-specific T helper 2 (Th2) cells cause experimental autoimmune encephalomyelitis in immunodeficient hosts rather than protect them from the disease.

Authors:  J J Lafaille; F V Keere; A L Hsu; J L Baron; W Haas; C S Raine; S Tonegawa
Journal:  J Exp Med       Date:  1997-07-21       Impact factor: 14.307

View more
  6 in total

1.  A hapten generated from an oxidation fragment of docosahexaenoic acid is sufficient to initiate age-related macular degeneration.

Authors:  Joe G Hollyfield; Victor L Perez; Robert G Salomon
Journal:  Mol Neurobiol       Date:  2010-03-12       Impact factor: 5.590

2.  Systemic and local anti-C5 therapy reduces the disease severity in experimental autoimmune uveoretinitis.

Authors:  D A Copland; K Hussain; S Baalasubramanian; T R Hughes; B P Morgan; H Xu; A D Dick; L B Nicholson
Journal:  Clin Exp Immunol       Date:  2009-12-04       Impact factor: 4.330

3.  Inhibitory peptide analogs derived from a major uveitogenic epitope protect from antiretinal autoimmunity by inducing type 2 and regulatory T cells.

Authors:  Lizette M Cortes; Dody Avichezer; Phyllis B Silver; Dror Luger; Mary J Mattapallil; Chi-Chao Chan; Rachel R Caspi
Journal:  J Leukoc Biol       Date:  2008-05-21       Impact factor: 4.962

4.  A suppressive oligodeoxynucleotide inhibits ocular inflammation.

Authors:  C Fujimoto; D M Klinman; G Shi; H Yin; B P Vistica; J D Lovaas; E F Wawrousek; T Igarashi; C-C Chan; I Gery
Journal:  Clin Exp Immunol       Date:  2009-06       Impact factor: 4.330

5.  Therapeutic dosing of fingolimod (FTY720) prevents cell infiltration, rapidly suppresses ocular inflammation, and maintains the blood-ocular barrier.

Authors:  David A Copland; Jian Liu; Lauren P Schewitz-Bowers; Volker Brinkmann; Karen Anderson; Lindsay B Nicholson; Andrew D Dick
Journal:  Am J Pathol       Date:  2011-11-24       Impact factor: 4.307

6.  Abrogation of Rbpj attenuates experimental autoimmune uveoretinitis by inhibiting IL-22-producing CD4+ T cells.

Authors:  Zaied Ahmed Bhuyan; Michihito Asanoma; Akiko Iwata; Chieko Ishifune; Yoichi Maekawa; Mitsuo Shimada; Koji Yasutomo
Journal:  PLoS One       Date:  2014-02-28       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.